SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (249)11/28/1997 9:54:00 PM
From: John McCarthy  Read Replies (2) of 569
 
Synvisc efficacy - Retrospective - Looks very good
==================================================

Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical
practice in Canada

(J RHEUMATOL 1996;23:1579-1585) ANDR, LUSSIER, ALFRED A. CIVIDINO, CHARLES A.
MCFARLANE, WOJCIECH P. OLSZYNSKI, WAYNE J. POTASHNER, RINALDO DE MDICIS,
SHERBROOKE, QC, VARIOUS CENTRES, ON,
SASKATOON, SK

Objective: To evaluate viscosupplementation with intraarticular hylan G-F 20 in current clinical practice.
Methods: A retrospective study of all patients with osteoarthritis of the knee treated with hylan by 5 Canadian
clinicians over a period of 2.5 years.
Results: A total of 1537 injections were performed in 336 patients involving 458 knees. The overall response and
the change of activity level were judged better or much better for 77 and 76% of the treated knees after the first
course of treatment (3 weekly injections), and 87 and 84% after a 2nd course. The mean time elapsing between the
first and 2nd course, 8.2 +/- 0.5 months, is an evaluation of the duration of benefits. Local adverse events were
observed in 28 patients (32 knees), with an overall rate of 2.7% adverse events per injection, 7.0% per joint, and
8.3% per patient. No systemic adverse events were noted in any patient. The adverse events were characterized by
pain and/or transient swelling of the injected joint, mostly mild or moderate in intensity, and 72% of the adverse events
were considered to be possibly or probably related to the injection. The incidence of adverse events is significantly
influenced by the injection technique: 5.2% adverse events per injection with a medial approach to a partially bent
knee, and 2.4% (straight medial) and 1.5% (straight lateral). After an adverse event, clinical improvement still
occurred in 69% of the affected knees.
Conclusion: Hylan G-F 20 provided good clinical benefits and an acceptable safety profile in current clinical
practice. The occurrence of adverse events after an intraarticular hylan injection is infrequent and unpredictable and is
not necessarily hylan related, although injection related.

FYI:
bestmdsite.com

Regards,

John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext